User profiles for Josee Zijlstra
Josée ZijlstraAssociate Professor of Hematology, VU University Medical Center, Amsterdam Verified email at vumc.nl Cited by 16017 |
[HTML][HTML] FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
…, G Testanera, OS Hoekstra, J Zijlstra… - European journal of …, 2015 - Springer
The purpose of these guidelines is to assist physicians in recommending, performing, interpreting
and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET …
and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET …
[PDF][PDF] Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in …
…, M Schwaiger, LH Schwartz, JM Zijlstra… - Journal of clinical …, 2007 - researchgate.net
… Based on the meta-analysis by Zijlstra et al,5 pooled sensitivity and specificity of FDG-PET
for detection of residual disease after completion of first-line therapy were 84% (95% CI, 71 …
for detection of residual disease after completion of first-line therapy were 84% (95% CI, 71 …
[HTML][HTML] FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
…, B Arends, FJ Verzijlbergen, JM Zijlstra… - European journal of …, 2010 - Springer
The aim of this guideline is to provide a minimum standard for the acquisition and interpretation
of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will …
of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will …
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 …
…, C Kobe, J Markova, C Renner, A Ho, J Zijlstra… - The Lancet, 2012 - thelancet.com
Background The intensity of chemotherapy and need for additional radiotherapy in patients
with advanced stage Hodgkin's lymphoma has been unclear. We did a prospective …
with advanced stage Hodgkin's lymphoma has been unclear. We did a prospective …
[HTML][HTML] Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma
…, JP De Boer, JM Zijlstra… - … England Journal of …, 2015 - Mass Medical Soc
Background Survivors of Hodgkin’s lymphoma are at increased risk for treatment-related
subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late …
subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late …
[HTML][HTML] The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
…, B Arends, FJ Verzijlbergen, J Zijlstra… - European journal of …, 2008 - Springer
Introduction Several studies have shown the usefulness of positron emission tomography (PET)
quantification using standardised uptake values (SUV) for diagnosis and staging, …
quantification using standardised uptake values (SUV) for diagnosis and staging, …
[PDF][PDF] Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
…, EM Noordijk, MW Louwman, JM Zijlstra… - J Clin Oncol, 2009 - academia.edu
… Noordijk, Marieke WJ Louwman, Josée M. Zijlstra, Hendrik van den Berg, Nicola S.
Russell, Margreet HA Baaijens Collection and assembly of data: Marie L. De Bruin, Judith …
Russell, Margreet HA Baaijens Collection and assembly of data: Marie L. De Bruin, Judith …
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
…, O Casasnovas, N Hamad, JM Zijlstra… - The Lancet …, 2020 - thelancet.com
Background Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive
cancer with a median overall survival of less than 6 months. We aimed to assess the …
cancer with a median overall survival of less than 6 months. We aimed to assess the …
[PDF][PDF] Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
…, Z Kral, R Greil, MS Topp, J Meissner, JM Zijlstra… - J Clin …, 2012 - medspec.co.za
Purpose In patients with early unfavorable Hodgkin’s lymphoma (HL), combined modality
treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and …
treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and …
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the …
…, C Kobe, A Lohri, R Greil, DA Eichenauer, JM Zijlstra… - The Lancet, 2017 - thelancet.com
Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses…
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses…